$MTVA up 40% 🚀 🔹 MetaVia ripping after obesity-drug data was selected for ADA 2026 Scientific Sessions 📈 🔹 DA-1726 is the key focus — a GLP-1/glucagon dual

$MTVA up 40% 🚀 🔹 MetaVia ripping after obesity-drug data was selected for ADA 2026 Scientific Sessions 📈 🔹 DA-1726 is the key focus — a GLP-1/glucagon dual agonist targeting obesity + MASH 🧬 🔹 Recent Phase 1 data showed strong weight-loss potential, improved glucose control, and favorable safe…